ML339

Overview

ML339 is a selective CXCR6 antagonist with an IC 50 of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC 50 of 0.3 μM and 1.4 μM, respectively. ML339 shows weaker activity against the recruitment of β-arrestin in mouse CXCR6 receptors, with an IC 50 of 18 μM. ML339 has no inhibitory effect on CXCR5 ， CXCR4 ， CXCR6 and apelin receptor (APJ) , with IC 50 >79 μM. ML339 has the potential to promote the development of prostate cancer research.

Application

Products | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR | Products > Signaling Pathways > Apelin Receptor (APJ) | Products > Signaling Pathways > Arrestin

Product Information

• Catalog No.: HY-122197
• CAS No.: 2579689-83-9
• Molecular Formula: C26H32ClN3O5
• Molecular Weight: 502.00
• Purity: 99.88%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 3.75 mg/mL (7.47 mM); Clear solution
• Availability: In-stock

Source

Original product source